Analysis of Biomarkers From Patients With Chorioretinal Diseases

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02026843

Enrollment

100

Registered

2014-01-03

Start date

2012-04-30

Completion date

2031-04-30

Last updated

2025-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Retinopathy, Macular Degeneration

Brief summary

This study was conducted to investigate the levels of ocular biomarkers from the patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration.

Detailed description

This prospective, case-control study included 50 patients(50eyes) with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. and 50 patient with nondiabetic retinopathy or cataract. Ocular fluids and blood samples were taken before injection of anti-vascular endothelial growth factor agent or pars plana vitrectomy for other retinal disease. Ocular biomarkers were analyzed.

Interventions

DRUGChorioretinal diseases

chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* age over 20 years * patients requiring ophthalmologic treatments for different degrees of decreasing of visual acuity. * patients with chorioretinal diseases including diabetic retinopathy, retinal vascular diseases, age-related macular degeneration (dry and wet), and retinal degeneration. * control patients asking cataract surgery or vitrectomy for posterior segment nonproliferative disorders.

Exclusion criteria

* under the age of 20 years * patients that received any anti-vascular endothelial growth factor agent for proliferative disease before taking sample of aqueous humor * patients that did not signed the informed consent of the trial * patients with intraocular inflammations or infections that requiring any pharmaceutical agent * patients with recent ocular trauma

Design outcomes

Primary

Measure	Time frame	Description
Biomarkers in ocular fluids	one month	To establish if certain type of chorioretinal diseases group are associated to different concentrations of gene or protein concentration.

Countries

South Korea

Contacts

Primary ContactDong Ho Park, M.D.

sarasate2222@gmail.com82-53-420-5813

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026